BioSpace News Archive

The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18 , 2020. Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie , outgoing Chair of the

FACIT, a commercialization venture firm, announced the newest recipients of Ontario First seed capital through the latest round of its Prospects Oncology Fund: Ottawa-based data science start-up Replica Analytics Ltd., and medtech innovator Dr. Greg Czarnota of Toronto’s Sunnybrook Research Institute.

Repurpose.AI, an AI drug discovery company, today announced a collaboration with Scripps Research to develop COVID-19 therapeutics.

BOX Bioscience has been at the forefront of manufacturing and distributing FDA approved and registered hand sanitizer products in response to the COVID-19 pandemic.

Biosenta Inc. listed on the CNSX is pleased to announce it is launching its disinfectant product called “True” in Canada.

Orig3n, Inc., a Boston-based company pioneering the future of wellness and health through diagnostics, genetics and biotechnology, has announced a comprehensive solution to provide COVID-19 testing for boarding schools.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale,

A new poll indicates that 59% of Canadians approve the use of psilocybin-mushrooms for terminally-ill patients.

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company’s recent developments during an investor webinar, hosted by RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.

Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Jude Samulski, PhD, President, Chief Scientific Officer and Co-founder, has been awarded an international patent application from the World Intellectual Property Organization (WO/2020/076892) for his regulated gene editing system